Q32 Bio shares their experience with Magnephy
We are very excited to share a recent testimonial from the Preclinical Research and Translational Biology team, at Q32 Bio, who have utilized Magnephy’s nanoscale microscopy solution to gain new insights. Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and severe inflammatory diseases.
“Q32 Bio has collaborated with Magnephy on several preclinical studies, and the experience has been outstanding. Magnephy brought a wealth of expertise to the table, carefully listening to the scientific questions we were trying to ask and suggesting potential solutions. During study execution the work was excellent, the communication prompt and clear, with regular check-ins to make sure they fully understood our needs and offers to modify the approach as the data emerged.
In the end, the results far exceeded even our most optimistic expectations, providing us with much deeper insight into the podocyte dynamics in our experiments and helping us quantify these effects. Moreover, the images Magnephy generated were breathtaking, providing a truly intuitive understanding of the underlying biology. This really was a case where a picture says a thousand words.
Without hesitation, we highly recommend Magnephy for their expertise in high resolution microscopy, their attention to their customers’ needs, and their ability to deliver rigorous and high impact scientific data. They are a fabulous group of scientists and Q32 Bio looks forward to continuing our collaboration with them.”
– Preclinical Research and Translational Biology, Q32 Bio
Everyone in the Magnephy team were very happy to receive such a glowing testimonial. The collaboration with Q32 Bio has been one of shared enthusiasm and we are very much looking forward to our continued collaboration in the future!
“It is very rewarding to receive such wonderful feedback from a valued collaboration partner and it is a strong confirmation for us that our nanoscale imaging technology truly can help pharmaceutical researchers gain new insights to drive pharmaceutical innovation.”
– Robin Ebbestad, CEO & Co-founder, Magnephy